ALEXAN

This brand name is authorized in Austria, Hong Kong SAR China, Israel, Malta, Poland, South Africa, Tunisia, Turkey.

Active ingredients

The drug ALEXAN contains one active pharmaceutical ingredient (API):

1	Cytarabine UNII 04079A1RDZ - CYTARABINE
	Cytarabine (ARA-C) is metabolised in vivo to ARA-CTP phosphorylated compound. This competitively inhibits DNA polymerase and may also inhibit certain acid kinase enzymes.
	Read more about Cytarabine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ALEXAN Solution for injection	MPI, EU: SmPC	Medicines Authority (MT)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01BC01	Cytarabine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BC Pyrimidine analogues
Discover more medicines within L01BC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
HK	Department of Health Drug Office	32544, 44691
IL	מִשְׂרַד הַבְּרִיאוּת	7698
MT	Medicines Authority	AA565/80801
PL	Rejestru Produktów Leczniczych	100003751, 100003774
TN	Direction de la Pharmacie et du Médicament	6943111, 6943112
TR	İlaç ve Tıbbi Cihaz Kurumu	8699205770096, 8699205770102
ZA	Health Products Regulatory Authority	T/26/161, T/26/162, T/26/82, T/26/83